ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
Stock Information for ContraFect Corporation
Loading
Please wait while we load your information from QuoteMedia.